The healthcare software group reports positive Phase I results for a novel schizophrenia treatment developed by its investment, Monument Therapeutics.
The brain health software group announces the posting of its annual report and notice of the upcoming Annual General Meeting.
The healthcare technology company has announced changes to its major shareholders.
The brain health software group reported a 23.7% revenue decline but reduced its EBITDA loss. Despite cost-cutting measures and recent order book growth, financial challenges and market headwinds persist.
The healthcare technology company will announce its preliminary results and host an investor presentation next month.
The healthcare technology company has secured a £1 million contract for a major Phase 3 autoimmune disease clinical trial, representing a significant opportunity to expand its presence in the high-impact CNS trials market.
The healthcare technology company has announced a change in shareholding, with an investor increasing their stake to over 10% of the company.
The healthcare technology company has secured two major contracts worth £1.2 million to provide digital cognitive and voice assessments for Phase 3 clinical trials in adolescent depression.
The neuroscience technology company's cognitive assessment platform was chosen for a large-scale brain health study, validating its capabilities and representing a significant market opportunity.
The neuroscience technology company has submitted a Letter of Intent to the FDA to develop an objective measure of cognitive impairment in schizophrenia, aiming to streamline clinical trials and accelerate treatment development.